» Articles » PMID: 33251712

The Demise of Islet Allotransplantation in the United States: A Call for an Urgent Regulatory Update

Abstract

Islet allotransplantation in the United States (US) is facing an imminent demise. Despite nearly three decades of progress in the field, an archaic regulatory framework has stymied US clinical practice. Current regulations do not reflect the state-of-the-art in clinical or technical practices. In the US, islets are considered biologic drugs and "more than minimally manipulated" human cell and tissue products (HCT/Ps). In contrast, across the world, human islets are appropriately defined as "minimally manipulated tissue" and not regulated as a drug, which has led to islet allotransplantation (allo-ITx) becoming a standard-of-care procedure for selected patients with type 1 diabetes mellitus. This regulatory distinction impedes patient access to islets for transplantation in the US. As a result only 11 patients underwent allo-ITx in the US between 2016 and 2019, and all as investigational procedures in the settings of a clinical trials. Herein, we describe the current regulations pertaining to islet transplantation in the United States. We explore the progress which has been made in the field and demonstrate why the regulatory framework must be updated to both better reflect our current clinical practice and to deal with upcoming challenges. We propose specific updates to current regulations which are required for the renaissance of ethical, safe, effective, and affordable allo-ITx in the United States.

Citing Articles

Demise of cadaveric islet transplantation in the USA: Quo Vadis, 1 year after BLA approval and 24 years after the Edmonton breakthrough?.

Witkowski P, Wojcik N, Appelbaum N, Fung J, Barth R, Ricordi C Front Transplant. 2025; 4:1491568.

PMID: 39949592 PMC: 11822476. DOI: 10.3389/frtra.2025.1491568.


Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects.

Rech Tondin A, Lanzoni G BioDrugs. 2025; 39(2):261-280.

PMID: 39918671 PMC: 11906537. DOI: 10.1007/s40259-025-00703-7.


An analysis of the UK national pancreas allocation scheme.

Gopal J, Gavan S, Burke K, Birch S, Augustine T Front Transplant. 2024; 3:1408838.

PMID: 39211732 PMC: 11358119. DOI: 10.3389/frtra.2024.1408838.


Regulatory approval of islet transplantation for treatment of type 1 diabetes: Implications and what is on the horizon.

Stabler C, Russ H Mol Ther. 2023; 31(11):3107-3108.

PMID: 37865099 PMC: 10638039. DOI: 10.1016/j.ymthe.2023.10.011.


Legal and Regulatory Challenges for Emerging Regenerative Medicine Solutions for Diabetes.

Thom R, Cronin A Transplantation. 2023; 108(5):1072-1079.

PMID: 37749797 PMC: 11042516. DOI: 10.1097/TP.0000000000004797.


References
1.
Byrne M, Hopkins D, Littlejohn W, Beckford R, Srinivasan P, Heaton N . Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and/or referred for islet transplantation to a specialist hypoglycaemia service. Horm Metab Res. 2014; 47(1):9-15. DOI: 10.1055/s-0034-1394455. View

2.
Iglesias-Lopez C, Agusti A, Obach M, Vallano A . Regulatory Framework for Advanced Therapy Medicinal Products in Europe and United States. Front Pharmacol. 2019; 10:921. PMC: 6728416. DOI: 10.3389/fphar.2019.00921. View

3.
Choudhary P, Rickels M, Senior P, Vantyghem M, Maffi P, Kay T . Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015; 38(6):1016-29. PMC: 4439532. DOI: 10.2337/dc15-0090. View

4.
Flatt A, Bennett D, Counter C, Brown A, White S, Shaw J . β-Cell and renal transplantation options for diabetes. Diabet Med. 2019; 37(4):580-592. DOI: 10.1111/dme.14177. View

5.
Marks P, Gottlieb S . Balancing Safety and Innovation for Cell-Based Regenerative Medicine. N Engl J Med. 2018; 378(10):954-959. DOI: 10.1056/NEJMsr1715626. View